Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
21,509 Breast Cancer
clinical trials

Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Anchorage, AK
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Anchorage, AK
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Boston, MA
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Bronx, NY
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Bronx, NY
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Canton, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Coon Rapids, MN
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Coos Bay, OR
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Des Moines, IA
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
East Syracuse, NY
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Effingham, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Ephrata, PA
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Fargo, ND
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Hazleton, PA
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Kernersville, NC
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Macomb, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Mechanicsville, VA
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Meridian, ID
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Missoula, MT
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Monroe, MI
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
New Ulm, MN
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Newark, DE
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Newark, DE
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Peoria, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Peoria, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Robbinsdale, MN
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Santa Fe, NM
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Seattle, WA
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Seattle, WA
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
State College, PA
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Statesville, NC
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Stillwater, MN
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Sullivan, MO
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Swansea, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Urbana, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Warren, MI
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
West Des Moines, IA
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Woodbury, MN
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Yelm, WA
Click here to add this to my saved trials
Oncology Clinical Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Yorkville, IL
Click here to add this to my saved trials
Triple-negative Breast Cancer Clinical Trial
Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Kansas City, KS
Click here to add this to my saved trials
Oncology Clinical Trial
Blossom Smart Expander Technology in Breast Reconstruction in Participants With Breast Cancer Undergoing Mastectomy
Status: Enrolling
Updated: 12/31/1969
mi
from
Stanford, CA
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Survey Study: Financial Impact of Breast Cancer Treatment
Status: Enrolling, Phase
Updated: 12/31/1969
mi
from
Sayre, PA
Click here to add this to my saved trials
Oncology Clinical Trial
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Houston, TX
Click here to add this to my saved trials
Oncology Clinical Trial
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Nashville, TN
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib + Sapacitabine in BRCA Mutant Breast Cancer
Status: Enrolling, Phase I, II
Updated: 12/31/1969
mi
from
Boston, MA
Click here to add this to my saved trials
Oncology Clinical Trial
Tilmanocept vs Sulfur Colloid in Sentinel Lymph Node Biopsy
Status: Enrolling, Phase IV
Updated: 12/31/1969
mi
from
Savannah, GA
Click here to add this to my saved trials
Oncology Clinical Trial
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Houston, TX
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Atlanta, GA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Atlanta, GA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Atlanta, GA
Click here to add this to my saved trials
Oncology Clinical Trial
A Study To Evaluate Escalating Doses of A Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Fairway, KS
Click here to add this to my saved trials
Oncology Clinical Trial
A Study To Evaluate Escalating Doses of A Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Nashville, TN
Click here to add this to my saved trials
Oncology Clinical Trial
A Study To Evaluate Escalating Doses of A Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Oncology Clinical Trial
Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Nashville, TN
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Oncology Clinical Trial
A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Chicago, IL
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
Oncology Clinical Trial
Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Madison, WI
Click here to add this to my saved trials
Oncology Clinical Trial
QUILT-3.017: Study of NEO-201 in Solid Tumors
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Bethesda, MD
Click here to add this to my saved trials
HER2-Positive Early Breast Cancer Clinical Trial
A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
HER2-Positive Early Breast Cancer Clinical Trial
A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Dallas, TX
Click here to add this to my saved trials
HER2-Positive Early Breast Cancer Clinical Trial
A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Peoria, IL
Click here to add this to my saved trials
Metastatic Breast Cancer Clinical Trial
Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer
Status: Enrolling, Phase I, II
Updated: 12/31/1969
mi
from
Boston, MA
Click here to add this to my saved trials
Metastatic Breast Cancer Clinical Trial
Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer
Status: Enrolling, Phase I, II
Updated: 12/31/1969
mi
from
Boston, MA
Click here to add this to my saved trials
Metastatic Breast Cancer Clinical Trial
Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer
Status: Enrolling, Phase I, II
Updated: 12/31/1969
mi
from
Dallas, TX
Click here to add this to my saved trials
Metastatic Breast Cancer Clinical Trial
Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer
Status: Enrolling, Phase I, II
Updated: 12/31/1969
mi
from
Newnan, GA
Click here to add this to my saved trials
Oncology Clinical Trial
Exercise Program in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
Status: Enrolling
Updated: 12/31/1969
mi
from
Hershey, PA
Click here to add this to my saved trials
Triple-negative Breast Cancer Clinical Trial
A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Breast Tumor Clinical Trial
Radiofrequency Chip for Localization of Non-Palpable Breast Lesions
Status: Enrolling
Updated: 12/31/1969
mi
from
Columbia, MO
Click here to add this to my saved trials
Breast Cancer Clinical Trial
DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Boston, MA
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Reducing Metabolic Syndrome Among Breast Cancer Survivors
Status: Enrolling
Updated: 12/31/1969
mi
from
Detroit, MI
Click here to add this to my saved trials
Oncology Clinical Trial
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
mi
from
Aberdeen, WA
Click here to add this to my saved trials
Oncology Clinical Trial
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
mi
from
Anaconda, MT
Click here to add this to my saved trials
Oncology Clinical Trial
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
mi
from
Anchorage, AK
Click here to add this to my saved trials
Oncology Clinical Trial
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
mi
from
Aurora, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
mi
from
Bloomington, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
mi
from
Boise, ID
Click here to add this to my saved trials
Oncology Clinical Trial
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
mi
from
Boise, ID
Click here to add this to my saved trials
Oncology Clinical Trial
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
mi
from
Bozeman, MT
Click here to add this to my saved trials
Oncology Clinical Trial
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
mi
from
Dayton, OH
Click here to add this to my saved trials
Oncology Clinical Trial
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
mi
from
Delaware, OH
Click here to add this to my saved trials
Oncology Clinical Trial
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
mi
from
East Stroudsburg, PA
Click here to add this to my saved trials
Oncology Clinical Trial
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
mi
from
Findlay, OH
Click here to add this to my saved trials
Oncology Clinical Trial
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
mi
from
Flint, MI
Click here to add this to my saved trials
Oncology Clinical Trial
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Oncology Clinical Trial
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
mi
from
Great Falls, MT
Click here to add this to my saved trials
Oncology Clinical Trial
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
mi
from
Greenville, OH
Click here to add this to my saved trials
Oncology Clinical Trial
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
mi
from
Greenville, SC
Click here to add this to my saved trials
Oncology Clinical Trial
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
mi
from
Greenville, SC
Click here to add this to my saved trials
Oncology Clinical Trial
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
mi
from
Kewanee, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
mi
from
Lacey, WA
Click here to add this to my saved trials
Oncology Clinical Trial
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
mi
from
Lancaster, OH
Click here to add this to my saved trials
Oncology Clinical Trial
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
mi
from
Meridian, ID
Click here to add this to my saved trials
Oncology Clinical Trial
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
mi
from
Newberg, OR
Click here to add this to my saved trials
Oncology Clinical Trial
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
mi
from
Princeton, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
mi
from
Springfield, OH
Click here to add this to my saved trials
1 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 215